The clearance was based on data from a single-arm multicenter clinical trial that evaluated the Omnipod 5 system in 80 children aged 2 to 5.9 years with type 1 diabetes. The Food and Drug ...
First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...
WASHINGTON -- The U.S. government has cleared the way for the first medical device that enables automated insulin dosing for people with type 2 diabetes. The plastic pod, called the Omnipod 5 ...
As Americans flock to nearby orchards for festive bouts of autumn apple picking, Insulet is celebrating a particularly bountiful stateside Apple harvest itself. The diabetes devicemaker has earned FDA ...
As Insulet continues on its path to roll out its next-generation wearable insulin pump this year—and just after passing the $1 billion annual sales mark—the diabetes management company is making a ...
“We are deeply committed to providing our Omnipod customers with the highest level of service and are confident our high-quality team has the skills and experience to assume direct distribution and ...
The Food and Drug Administration (FDA) has approved use of the Omnipod 5 automated insulin delivery system (Insulet Corp) for children aged 2 years and older with type 1 diabetes, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback